Tafamidis

• Background :

  Tafamidis functions as a chaperone that stabilizes the correctly folded tetrameric form of the transthyretin (TTR) protein by binding in one of the two thyroxine-binding sites of the tetramer (1). In drug form, it is used to delay impairment of peripheral nerve function in adults with familial amyloid polyneuropathy.

• Description :

  Transthyretin Dissociation Inhibitor

• Product Name Alternative :

  2- (3,5-Dichlorophenyl) -1,3-Benzoxazole-6-Carboxylic Acid, FX-1006, 2- (3,5-Dichlorophenyl) -6-benzoxazole carboxylic acid

• UNSPSC :

  41116105

• Type :

  Inhibitor

• Source :

  Synthetic

• Field of Research :

  Alzheimer's Disease | Axon Markers | Cell Markers | Cell Signaling | Cytoskeleton | Microtubules | MT Associated Proteins | Neurodegeneration | Neuron Markers | Neuroscience | Tangles & Tau

• Purity :

  >98% (TLC) ; NMR (Conforms)

• Weight :

  0.005

• Format :

  Off-white powder

• Solubility :

  May be dissolved in DMSO (25 mg/ml, warm)

• Molecular Formula :

  C14H7Cl2NO3

• Molecular Weight :

  308.1

• Precautions :

  Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

• References & Citations :

  1. Said G, Grippon S, Kirkpatrick P. (2012). Nature Reviews. Drug Discovery. 11(3): 185–186.

• CAS Number :

  594839-88-0